{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:16:43Z","timestamp":1778505403826,"version":"3.51.4"},"reference-count":34,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"F. Hoffmann-La Roche, Ltd"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The use of long-term oxygen therapy (LTOT) in idiopathic pulmonary fibrosis (IPF) is poorly studied. We assessed the proportion of patients with IPF receiving LTOT and compared the risk of death according to LTOT exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the French national healthcare claims database, the use of LTOT and antifibrotics was studied in patients newly diagnosed with IPF from 1 January 2012 to 31 December 2019, followed until 31 December 2021. An adjusted Cox regression model was used to compare the risk of death by LTOT use, using exposure to antifibrotics and LTOT as time-dependent variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 16\u2009003 patients newly diagnosed with IPF, 4559 (28.5%) initiated LTOT during follow-up: median time to initiation was 273 days and median duration was 336 days. The proportion of patients initiating LTOT was 23.2% among those not receiving antifibrotics (78.5% of study population) and 42.0% in those treated by antifibrotics at inclusion (7.7%), with respective median time to LTOT initiation of 110 and 590 days, and respective median LTOT duration of 308 and 294 days. Patients exposed to LTOT had a significantly higher risk of death compared with those who were not (HR: 2.9 (95% CI: 2.8 to 3.0) among those without antifibrotics; 2.1 (95% CI 1.9 to 2.3) among those with concomitant antifibrotics).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of LTOT is limited among patients with IPF, even those receiving antifibrotics. The association between LTOT and mortality suggests that LTOT use is a marker of severity. Guidelines dissemination would help clinicians adopt appropriate LTOT management in patients with IPF and chronic respiratory failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003153","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:50:50Z","timestamp":1760093450000},"page":"e003153","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Use of supplemental oxygen therapy in idiopathic pulmonary fibrosis: an observational real-life study in 16 003 patients"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-8605","authenticated-orcid":false,"given":"Claire","family":"Marant-Micallef","sequence":"first","affiliation":[{"name":"PELyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Belhassen","sequence":"additional","affiliation":[{"name":"PELyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Fourrier","sequence":"additional","affiliation":[{"name":"Association Fibroses Pulmonaires France, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maeva","family":"Nolin","sequence":"additional","affiliation":[{"name":"PELyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nad\u00e8ge","family":"Bornier","sequence":"additional","affiliation":[{"name":"PELyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1949-3461","authenticated-orcid":false,"given":"St\u00e9phane","family":"Jouneau","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Pontchaillou Hospital, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Departments of Pneumology, Marienhaus Clinic Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Samara","sequence":"additional","affiliation":[{"name":"F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"UMR 754, INRAE, Universit\u00e9 Claude Bernard Lyon 1, F-69100, Villeurbanne, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Pulmonaires Rares, Service de Pneumologie, F-69000, Hospices Civils de Lyon, ERN-LUNG, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2026013003401091000_12.1.e003153.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1020-3","article-title":"The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry","volume":"20","author":"Kreuter","year":"2019","journal-title":"Respir Res"},{"key":"2026013003401091000_12.1.e003153.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30866-8"},{"key":"2026013003401091000_12.1.e003153.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2026013003401091000_12.1.e003153.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2026013003401091000_12.1.e003153.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00217614"},{"key":"2026013003401091000_12.1.e003153.6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026013003401091000_12.1.e003153.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2026013003401091000_12.1.e003153.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01714-y","article-title":"Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis","volume":"22","author":"Belhassen","year":"2021","journal-title":"Respir Res"},{"key":"2026013003401091000_12.1.e003153.9","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00006812"},{"key":"2026013003401091000_12.1.e003153.10","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.rmr.2022.01.014","article-title":"French practical guidelines for the diagnosis and management of IPF - 2021 update, full version","volume":"39","author":"Cottin","year":"2022","journal-title":"Rev Mal Respir"},{"key":"2026013003401091000_12.1.e003153.11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.rmr.2017.07.022","article-title":"French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis: 2017 update. Summary","volume":"34","author":"Cottin","year":"2017","journal-title":"Rev Mal Respir"},{"key":"2026013003401091000_12.1.e003153.12","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001814"},{"key":"2026013003401091000_12.1.e003153.13","unstructured":"Cottin V . Fibrose pulmonaire idiopathique: protocole national de diagnostic et de soins. Centre de r\u00e9f\u00e9rence des maladies pulmonaires rares. 2021."},{"key":"2026013003401091000_12.1.e003153.14","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-206865","article-title":"British Thoracic Society guidelines for home oxygen use in adults","volume":"70 Suppl 1","author":"Hardinge","year":"2015","journal-title":"Thorax"},{"key":"2026013003401091000_12.1.e003153.15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.rmr.2017.09.005","article-title":"French recommendations for idiopathic pulmonary fibrosis: An updated working document for clinicians","volume":"34","author":"Cottin","year":"2017","journal-title":"Rev Mal Respir"},{"key":"2026013003401091000_12.1.e003153.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2013-000007","article-title":"A qualitative study of informal caregivers\u2019 perspectives on the effects of idiopathic pulmonary fibrosis","volume":"1","author":"Belkin","year":"2014","journal-title":"BMJ Open Respir Res"},{"key":"2026013003401091000_12.1.e003153.17","doi-asserted-by":"publisher","DOI":"10.1111\/jan.12587"},{"key":"2026013003401091000_12.1.e003153.18","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0080-2016","article-title":"Oxygen therapy for interstitial lung disease: a systematic review","volume":"26","author":"Bell","year":"2017","journal-title":"Eur Respir Rev"},{"key":"2026013003401091000_12.1.e003153.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-022-01976-0","article-title":"Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis","volume":"23","author":"Kreuter","year":"2022","journal-title":"Respir Res"},{"key":"2026013003401091000_12.1.e003153.20","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65 Suppl 4","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2026013003401091000_12.1.e003153.21","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"2026013003401091000_12.1.e003153.22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.802989","article-title":"Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics","volume":"8","author":"Cottin","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026013003401091000_12.1.e003153.23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01299-2023","article-title":"Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis","volume":"62","author":"Dempsey","year":"2023","journal-title":"Eur Respir J"},{"key":"2026013003401091000_12.1.e003153.24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1513\/AnnalsATS.202308-697RL","article-title":"Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016-2022","volume":"21","author":"Shankar","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026013003401091000_12.1.e003153.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.04.037"},{"key":"2026013003401091000_12.1.e003153.26","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216749"},{"key":"2026013003401091000_12.1.e003153.27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01563-2020","article-title":"Moderate resting hypoxaemia in fibrotic interstitial lung disease","volume":"57","author":"Khor","year":"2021","journal-title":"Eur Respir J"},{"key":"2026013003401091000_12.1.e003153.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40508-8","article-title":"Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy","volume":"13","author":"Kataoka","year":"2023","journal-title":"Sci Rep"},{"key":"2026013003401091000_12.1.e003153.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3608ST"},{"key":"2026013003401091000_12.1.e003153.30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(23)00100-5","article-title":"International guideline recommendations and eligibility criteria for home oxygen therapy","volume":"11","author":"Saleem","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026013003401091000_12.1.e003153.31","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1513\/AnnalsATS.201705-372OC","article-title":"Oxygen Therapy for Interstitial Lung Disease: Physicians\u2019 Perceptions and Experiences","volume":"14","author":"Khor","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026013003401091000_12.1.e003153.32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00421-2019","article-title":"Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey","volume":"54","author":"Lim","year":"2019","journal-title":"Eur Respir J"},{"key":"2026013003401091000_12.1.e003153.33","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0066-2023","article-title":"Barriers to and facilitators of the use of oxygen therapy in people living with an interstitial lung disease: a systematic review of qualitative evidence","volume":"32","author":"Tikellis","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2026013003401091000_12.1.e003153.34","doi-asserted-by":"publisher","DOI":"10.1159\/000490667"}],"updated-by":[{"DOI":"10.1136\/bmjresp-2025-003153corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000}}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:40:23Z","timestamp":1769773223000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjresp-2025-003153"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003153","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}